

NCT02348918 Raw comparison:

Summary:
CHIA has 31 criteria while your personal folder has 34 criteria
Total found criteria: 30/31
Total not Found: 1/31
Total Extra: 3
This trial is INVALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Male or female 18 years of age or older            │ Male or female 18 years of age or older            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Study eye with clinically significant diabetic     │ Study eye with clinically significant diabetic     │
│ macular edema (DME) with central subfield          │ macular edema (DME) with central subfield          │
│ thickness ≥ 350µm on spectral domain OCT           │ thickness ≥ 350µm on spectral domain OCT           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Best corrected visual acuity (BCVA) of 20/50 to    │ Best corrected visual acuity (BCVA) of 20/50 to    │
│ 20/320 ETDRS equivalent (65 letters to 23 letters) │ 20/320 ETDRS equivalent (65 letters to 23 letters) │
│ in the study eye with BCVA decrement primarily     │ in the study eye with BCVA decrement primarily     │
│ attributable to DME                                │ attributable to DME                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Treatment naïve i e no previous anti-VEGF          │ Treatment naïve i e no previous anti-VEGF          │
│ treatment in the study eye or no anti-VEGF         │ treatment in the study eye or no anti-VEGF         │
│ treatment in the 45 days prior to study enrollment │ treatment in the 45 days prior to study enrollment │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ In the investigator's opinion the subject still    │ In the investigator's opinion the subject still    │
│ has significant intraretinal fluid with room for   │ has significant intraretinal fluid with room for   │
│ improvement in both macular edema and BCVA         │ improvement in both macular edema and BCVA         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Willing and able to return for all study visits    │ Willing and able to return for all study visits    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Able to meet the extensive post-op evaluation      │ Able to meet the extensive post-op evaluation      │
│ regimen                                            │ regimen                                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Understands and signs the informed consent form    │ Understands and signs the informed consent form    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Active proliferative diabetic retinopathy (PDR) in │ Active proliferative diabetic retinopathy (PDR) in │
│ the study eye such as NVE NVD vitreous hemorrhage  │ the study eye such as NVE NVD vitreous hemorrhage  │
│ or neovascular glaucoma                            │ or neovascular glaucoma                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Uncontrolled hypertension defined as systolic >180 │ Uncontrolled hypertension defined as systolic      │
│ mmHg or > 160 mmHg on 2 consecutive measurements   │ \>180 mmHg or \> 160 mmHg on 2 consecutive         │
│ or diastolic > 100 mmHg on optimal medical regimen │ measurements or diastolic \> 100 mmHg on optimal   │
│                                                    │ medical regimen                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Screening HgA1c blood test > 10 0                  │ Screening HgA1c blood test \> 10 0                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Focal laser photocoagulation or                    │ Focal laser photocoagulation or                    │
│ intravitreal/periocular steroids of any type in    │ intravitreal/periocular steroids of any type in    │
│ the study eye within the last 90 days prior to     │ the study eye within the last 90 days prior to     │
│ study enrollment                                   │ study enrollment                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ A history of intravitreal anti-VEGF injection of   │ A history of intravitreal anti-VEGF injection of   │
│ any type in the study eye within the last 45 days  │ any type in the study eye within the last 45 days  │
│ prior to study enrollment                          │ prior to study enrollment                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of rhegmatogenous retinal detachment       │ History of rhegmatogenous retinal detachment       │
│ retinal tear(s) or traction retinal detachments in │ retinal tear(s) or traction retinal detachments in │
│ the study eye                                      │ the study eye                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Epiretinal membrane and/or vitreomacular traction  │ Epiretinal membrane and/or vitreomacular traction  │
│ in the study eye as determined by the central      │ in the study eye as determined by the central      │
│ reading center                                     │ reading center                                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Previous pars plana vitrectomy in the study eye    │ Previous pars plana vitrectomy in the study eye    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any intraocular surgery in the study eye within    │ Any intraocular surgery in the study eye within    │
│ the last 90 days prior to study enrollment         │ the last 90 days prior to study enrollment         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ YAG laser treatment in the study eye in last 30    │ YAG laser treatment in the study eye in last 30    │
│ days prior to study enrollment                     │ days prior to study enrollment                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ High myopia in the study eye with a spherical      │ High myopia in the study eye with a spherical      │
│ equivalent of >8 00D at screening                  │ equivalent of \>8 00D at screening                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Other ocular pathologies that in the               │ Other ocular pathologies that in the               │
│ investigator's opinion would interfere with the    │ investigator's opinion would interfere with the    │
│ subject's vision in the study eye                  │ subject's vision in the study eye                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Chronic or recurrent uveitis                       │ Chronic or recurrent uveitis                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Ongoing ocular infection or inflammation in either │ Ongoing ocular infection or inflammation in either │
│ eye                                                │ eye                                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ A history of cataract surgery                      │ A history of cataract surgery                      │
│ complications/vitreous loss in the study eye       │ complications/vitreous loss in the study eye       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Congenital eye malformations in the study eye      │ Congenital eye malformations in the study eye      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ A history of penetrating ocular trauma in the      │ A history of penetrating ocular trauma in the      │
│ study eye                                          │ study eye                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Mentally handicapped                               │ Mentally handicapped                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Pregnant female as determined for women less than  │ Pregnant female as determined for women less than  │
│ 60 years old by a positive urine pregnancy test    │ 60 years old by a positive urine pregnancy test    │
│ during the screening window                        │ during the screening window                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Nursing female                                     │ Nursing female                                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Currently participating in any other clinical      │ Currently participating in any other clinical      │
│ research study                                     │ research study                                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Contraindication to the study medication           │ Contraindication to the study medication           │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



╒══════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ CHIA Criteria Not Found in Personal                                                                  │
╞══════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ Intra-Ocular Pressure (IOP) is under control (i e IOP ≤ 25 mm in the study eye) and study eye is not │
│ receiving any IOP lowering drops                                                                     │
╘══════════════════════════════════════════════════════════════════════════════════════════════════════╛



╒═════════════════════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                                         │
╞═════════════════════════════════════════════════════════════════════════════════╡
│ Intra-Ocular Pressure (IOP) is under control (i e IOP                           │
├─────────────────────────────────────────────────────────────────────────────────┤
│ ≤ 25 mm in the study eye) and study eye is not receiving any IOP lowering drops │
├─────────────────────────────────────────────────────────────────────────────────┤
│ Must have minimum age of 18 Years                                               │
╘═════════════════════════════════════════════════════════════════════════════════╛